 | This article needs to beupdated. Please help update this article to reflect recent events or newly available information.(February 2025) |
 | |
| Clinical data | |
|---|---|
| Other names | CVL-231; PF-06852231 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C20H21F3N4O |
| Molar mass | 390.410 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Emraclidine (developmental code namesCVL-231,PF-06852231) is an investigationalantipsychotic for the treatment of bothschizophrenia andAlzheimer's disease psychosis developed byCerevel Therapeutics.[1][2] As of August 2024, it is inphase 2clinical trials.[1][3]
Emraclidine is apositive allosteric modulator that selectively targets themuscarinic acetylcholine receptor M4 subtype. The M4 receptor subtype is expressed in thestriatum of the brain, which plays a key role in regulatingacetylcholine anddopamine levels. An imbalance of these neurotransmitters has been linked to psychotic symptoms in schizophrenia. Unlike othermuscarinic receptors, M4 receptor subtypes are selectively expressed in the striatum and activation of these receptors has been shown to indirectly regulate dopamine levels without blockingD2/D3 receptors, which may lead to unwanted motor side effects seen in current antipsychotics.[4]
 | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |